SAB Biotherapeutics Inc. Common Stock (SABS)
Stock · NASDAQ · Health Care
$2.54as of 10/16/2026
Price chart
Active signals
SABS Signal Track Record
How signals performed across all stocks →What SABS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | 0.0% | 47% | September 25, 2026 |
| Bollinger Band Breakdown | 24 | -10.1% | 25% | October 1, 2026 |
| Bollinger Band Breakout | 18 | -6.9% | 33% | April 15, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +2.4% | 50% | August 21, 2026 |
| Any 20-session window (baseline) | -4.3% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SABS
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 86
- Website
- www.sab.bio/
Fundamentals
- 1-day range
- $2.47$2.63
- Market cap
- $294.39M
- P/E (trailing)
- 17.75
- P/E (forward)
- -2.65
- EPS (trailing)
- $-1.42
- Dividend yield
- —
- Beta
- 0.79
- Avg. volume
- 526.1K
How SAB Biotherapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Apr 14, 2023 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
SAB Biotherapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SABSSAB Biotherapeutics Inc. Common Stock$2.53▼ 2.32%Market cap $294.39MP/E 17.75$2.1$5.15
- FATEFate Therapeutics Inc. Common Stock$1.79▼ 7.25%Market cap $290.23MP/E —$0.95$3.23
- NMRANeumora Therapeutics Inc. Common Stock$0.474▲ 11.01%Market cap $303.87MP/E —$0.3154$3.65
- AVXLAnavex Life Sciences Corp. Common Stock$1.31▼ 11.49%Market cap $303.96MP/E —$1.56$10.38
- EDITEditas Medicine Inc. Common Stock$2.35▼ 3.69%Market cap $283.93MP/E —$1.66$4.33
- LCTXLineage Cell Therapeutics Inc. Common Stock$0.98▼ 1.01%Market cap $281.71MP/E —$0.8823$2.09
- IKTInhibikase Therapeutics Inc. Common Stock$1.65▼ 9.84%Market cap $318.20MP/E —$1.33$2.61
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SABS SAB Biotherapeutics Inc. Common Stock | $294.39M | 17.75 | $2.53 | ▼ 2.32% | $2.1$5.15 |
| FATE Fate Therapeutics Inc. Common Stock | $290.23M | — | $1.79 | ▼ 7.25% | $0.95$3.23 |
| NMRA Neumora Therapeutics Inc. Common Stock | $303.87M | — | $0.474 | ▲ 11.01% | $0.3154$3.65 |
| AVXL Anavex Life Sciences Corp. Common Stock | $303.96M | — | $1.31 | ▼ 11.49% | $1.56$10.38 |
| EDIT Editas Medicine Inc. Common Stock | $283.93M | — | $2.35 | ▼ 3.69% | $1.66$4.33 |
| LCTX Lineage Cell Therapeutics Inc. Common Stock | $281.71M | — | $0.98 | ▼ 1.01% | $0.8823$2.09 |
| IKT Inhibikase Therapeutics Inc. Common Stock | $318.20M | — | $1.65 | ▼ 9.84% | $1.33$2.61 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetesbenzinga · 10/13/2026
- SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research CongressYahoo · 10/1/2026
- SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of DiabetesYahoo · 9/22/2026
Insider Activity
Insider Actions →- Alexandra Kropotova · September 17, 2026 · Tax Withholding473
- Alexandra Kropotova · June 25, 2026 · Tax Withholding988
Institutional Ownership
March 31, 2026
- Total shares held
- 68.41M
- Total value held
- $261.81M
- Institutional holders
- 75
- Unknown11.42M
- Unknown7.97M
- Unknown6.43M
- Unknown4.40M
- Unknown4.40M
- Unknown3.76M
- Unknown3.41M
- Unknown3.03M
- Unknown2.85M
- Unknown2.49M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
SAB Biotherapeutics to Present SAB-142 Data at European Diabetes Meeting
SAB Biotherapeutics will share results for its SAB‑142 program at the 62nd Annual Meeting of the European Association for the Study of Diabetes. The presentation offers a chance to update investors on the clinical progress of this diabetes therapy. The company’s stock is currently trading near its 15‑touch support level of $3.70 and shows a volume spike, indicating growing interest.
SAB Biotherapeutics to Present SAB-142 Data at European Diabetes Meeting. SAB Biotherapeutics will share results for its SAB‑142 program at the 62nd Annual Meeting of the European Association for the Study of Diabetes. The presentation offers a chance to update investors on the clinical progress of this diabetes therapy. The company’s stock is currently trading near its 15‑touch support level of $3.70 and shows a volume spike, indicating growing interest.